Emyria Company Description

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.

It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications.

The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name.

It has a collaboration partnership with the University of Western Australia to support the advancement of Emyria’s MDMA analogue drug development program, targeting mental health and neurodegenerative diseases, including Parkinson’s.

The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020.

Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Emyria Limited

Country	Australia
Founded	2018
Industry	Health Information Services
Sector	Healthcare
CEO	Michael Winlo

Contact Details

Address: D2, 661 Newcastle Street Leederville, 6007 Australia
Phone	61 8 6559 2800
Website	emyria.com

Stock Details

Ticker Symbol	EMD
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000073645
SIC Code	2834

Key Executives

Name	Position
Dr. Michael Winlo	MD and Director
Dr. Alistair Vickery	Executive Medical Director and Director
Joseph Daniel Ohayon ACA, MBA Intl Bus.	Chief Financial Officer
Tracie Ernenwein	Head of Research and Drug Development
Mary-Ann Rennie	Head of Corporate Operations
Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin	Company Secretary